Miyako Capital has contributed to a series A round for the cancer vaccine developer, which expanded to Japan last year.
VLP Therapeutics, a US-based cancer vaccine developer, secured $15m yesterday in a series A round that included Miyako Capital, a venture capital vehicle for Kyoto University.
Chemicals producer Konishiyasu and diversified conglomerate Sojitz also participated in the round, as did SK Impact Fund, RJ Fund and private investor Robert Hisaoka, all three of which were identified as existing backers.
VLP’s lead product candidate is a cancer vaccine but it is also working on prophylactic vaccines for malaria, dengue…
